MedTrace Logo

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

NCT06718816 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2024-12-05

No results posted yet for this study

Summary

This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.

Conditions

  • Wet Age-related Macular Degeneration (wAMD)

Sponsors & Collaborators

  • Beijing Anlong Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-09
Primary Completion
2029-06-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06718816 on ClinicalTrials.gov